Global Biopharmaceutical CMO And CRO Market Size study, by Source (Mammalian, Non-mammalian), By Service (Contract Manufacturing, Contract Research), By Product (Biologics, Biosimilars) and Regional Forecasts 2022-2028

Global Biopharmaceutical CMO And CRO Market Size study, by Source (Mammalian, Non-mammalian), By Service (Contract Manufacturing, Contract Research), By Product (Biologics, Biosimilars) and Regional Forecasts 2022-2028

Global Biopharmaceutical CMO And CRO Market is valued at approximately USD 27.6 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.6 % over the forecast period 2022-2028. Biopharmaceutical CMO And CRO are contract manufacturing organizations and contract research organizations. It basically provides research and development services and focuses on manufacturing. The rising demand for biopharmaceuticals has led to the adoption of Biopharmaceutical CMO And CRO across the forecast period. For Instance: according to the Information Technology & Innovation Foundation in 2020, the demand and adoption of biopharmaceutical industries is increasing rapidly worldwide. As per the source, the industry is contributing a huge amount to the U.S economy and providing employment to around 50,0000 workers. The source also states that due to increasing demand China is striving to become the leading region in biopharmaceuticals. Increasing investment by CMOs for capacity expansion enhances the market growth of Biopharmaceutical CMO And CRO. Also, with the rising investment in pharmaceutical industry, the adoption & demand for Biopharmaceutical CMO And CRO is likely to increase the market growth during the forecast period. However, limited outsourcing amongst well-established biopharmaceutical manufacturers impedes the growth of the market over the forecast period of 2022-2028.

The geographical regions considered for the global Biopharmaceutical CMO And CRO market analysis include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America dominated the market across the world for Biopharmaceutical CMO And CRO and projected the largest revenue share owing to the presence of small and mid-size biopharmaceutical industries and well-equipped resources. Whereas, Asia-Pacific is also estimated to be the rapidly growing region during 2022-2028. The Biopharmaceutical CMO And CRO market is tremendously growing because of factors such as lower operating costs and labor costs.

Major market players included in this report are:
Boehringer Ingelheim GmbH
Lonza Group AG
Inno Biologics Sdn Bhd
Rentschler Biopharma SE
JRS Pharma
Biomeva GmbH
ProBioGen AG
Fujifilm Diosynth Biotechnologies U.S.A., Inc.
Toyobo Co., Ltd.
Samsung Biologics

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Source:
Mammalian
Non-mammalian
By Service:
Contract Manufacturing
Contract Research
By Product:
Biologics
Biosimilars
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Biopharmaceutical CMO And CRO Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Boehringer Ingelheim GmbH
Lonza Group AG
Inno Biologics Sdn Bhd
Rentschler Biopharma SE
JRS Pharma
Biomeva GmbH
ProBioGen AG
Fujifilm Diosynth Biotechnologies U.S.A., Inc.
Toyobo Co., Ltd.
Samsung Biologics

Please note:The single user license is non-downloadable and non-printable. Global Site license will allow these actions.